- Medical School - Medical University of South Carolina (2010-2014)
- Residency - Baylor College of Medicine (2014-2018), Neurology
- Fellowship - MD Anderson Cancer Center (2018-2020), Neuro-oncology
Michael Youssef, M.D.
Michael Youssef, M.D., is an Assistant Professor in the Department of Neurology and the Department of Hematology and Oncology at UT Southwestern Medical Center. He specializes in neuro-oncology.
Dr. Youssef earned his medical degree at the Medical University of South Carolina. He completed a residency in neurology at Baylor College of Medicine and then received advanced training in neuro-oncology through a fellowship at the University of Texas MD Anderson Cancer Center.
Certified by the American Board of Psychiatry and Neurology, he joined the UT Southwestern faculty in 2020.
Dr. Youssef’s clinical and research interests include glioblastoma; primary brain tumors; rare brain tumors, including ependymoma and medulloblastoma; neurologic complications of systemic cancer therapy; brain metastasis; and leptomeningeal disease.
He is a member of the American Academy of Neurology, the American Brain Tumor Association, the Society for Neuro-Oncology, and the American Society for Clinical Oncology.
- American Academy of Neurology
- American Brain Tumor Association
- Society for Neuro-Oncology
- American Society for Clinical Oncology
- American Brain Tumor Association, Summer research grant recipient 2011-2011, Research performed on GBM imaging and response to Temozolomide in patients exposed to O6-BG
- Chief Fellow, MD Anderson Cancer Center Department of Neuro-Oncology 2019-2020
Metabolic and Nutritional Nervous System Dysfunction in Cancer Patients in Neurological Complications of Systemic Cancer and Antineoplastic Therapy, Second Edition
Youssef M, Beal T, Mandel J (2020), Newton/Malkin
Recent Advances for Targeted Therapies in Glioblastoma in Advances in Biology and Treatment of Glioblastoma
Youssef M., Mandel J., Chowdhary S., Kesari S. (2017), Springer
- Metabolic and Nutritional Nervous System Dysfunction in Cancer Patients in Neurological Complications of Systemic Cancer and Antineoplastic Therapy, Second Edition
Distance traveled to glioblastoma treatment: A measure of the impact of socioeconomic status on survival.
Bird CE, Traylor JI, Youssef M, Abdullah KG, Clinical neurology and neurosurgery 2021 Aug 209 106909
A prospective study of posttraumatic growth as assessed by self-report and family caregiver in the context of advanced cancer.
Moore AM, Gamblin TC, Geller DA, Youssef MN, Hoffman KE, Gemmell L, Likumahuwa SM, Bovbjerg DH, Marsland A, Steel JL, Psycho-oncology 2011 May 20 5 479-87
Neurologic complications of immune checkpoint inhibitors in cancer patients.
Youssef M, Woodman K Neurology 2018
Effect of health disparities on overall survival of patients with glioblastoma.
Mandel JJ, Youssef M, Nam J, Patel AJ, Jalali A, Ludmir EB, Liu D, Wu J, Armstrong G, Huse J, Bondy M, de Groot JF, Journal of neuro-oncology 2019 Apr 142 2 365-374
Treatment strategies for glioblastoma in older patients: age is just a number.
Youssef M, Ludmir EB, Mandel JJ, Patel AJ, Jalali A, Treiber J, Wu J, McAleer MF, de Groot JF, Journal of neuro-oncology 2019 Oct
Recent Advances for Targeted Therapies in Glioblastoma. In: Somasundaram K. (eds) Advances in Biology and Treatment of Glioblastoma.
Youssef M., Mandel J., Chowdhary S., Kesari S. Current Cancer Research 2017
Randomized controlled trial of a collaborative care intervention to manage cancer-related symptoms: lessons learned.
Steel J, Geller DA, Tsung A, Marsh JW, Dew MA, Spring M, Grady J, Likumahuwa S, Dunlavy A, Youssef M, Antoni M, Butterfield LH, Schulz R, Day R, Helgeson V, Kim KH, Gamblin TC, Clinical trials (London, England) 2011 Jun 8 3 298-310
Highlighting the need for reliable clinical trials in glioblastoma.
Mandel JJ, Youssef M, Ludmir E, Yust-Katz S, Patel AJ, De Groot JF, Expert review of anticancer therapy 2018 10 18 10 1031-1040
Recurrent Papillary Glioneuronal Tumor.
Goethe EA, Youssef M, Patel AJ, Jalali A, Goodman JC, Mandel JJ, World neurosurgery 2019 Aug 128 127-130
IDH mutation status and the development of venous thromboembolism in astrocytoma patients.
Mandel JJ, Youssef M, Yust-Katz S, Patel AJ, Jalali A, Li Z, Wu J, Ludmir EB, de Groot JF, Journal of the neurological sciences 2021 Jun 427 117538
Treatment Strategies for Glioblastoma in Older Patients: Age is Just a Number.
Youssef M., Ludmir E., Mandel J., Patel AJ., Jalali A., Treiber J., Wu J., McAleer M., de Groot J. Journal of Neuro-Oncology 2019 145 357-364
Physical and psychological functioning of polytrauma patients with traumatic brain injury at 10+ years follow-up.
Steel JL, Youssef M, Ramirez J, Probst C, Pfeifer R, Zele BA, Sittaro N-A, Khalifa F, Pape HC Journal of Trauma 2009
Health-related quality of life in patients with multiple injuries and traumatic brain injury 10+ years postinjury.
Steel J, Youssef M, Pfeifer R, Ramirez JM, Probst C, Sellei R, Zelle BA, Sittaro NA, Khalifa F, Pape HC, The Journal of trauma 2010 Sep 69 3 523-30; discussion 530-1
Paraneoplastic syndromes in small cell lung cancer
Soomro Z, Youssef M, Yust-Katz S, Jalali A, Patel A, Mandel J Journal of Thoracic Disease 2020
- Distance traveled to glioblastoma treatment: A measure of the impact of socioeconomic status on survival.
- Cancer Neurology
- Low-Grade Gliomas
- Rare Brain Tumors
- Primary Brain Tumors
- Rare Brain Tumors